medigraphic.com
ISSN 2992-8559 (Electronic)
ISSN 1405-0625 (Print)

2010, Number 3

<< Back

Cir Plast 2010; 20 (3)

Volumetric facial rejuvenation with hyaluronic acid

Espinosa MS, Priego BR, Hoz BME

Language: Spanish
References: 17
Page: 133-139
PDF size: 459.82 Kb.


ABSTRACT

The non animal stabilized hyaluronic acid has been widely used since it was approved by the COFEPRIS in 2000 for the treatment of wrinkles, folds and since 2006 what is used for atrophy of soft face tissues such as the malar area, the chin or in the jaw, etc. Having hyaluronic acid with different characteristics, number of reticulations and concentration per milliliter, to produce subtypes makes the product very versatile and permits refinement in facial volume rejuvenation. An action mechanism indications, precautions and recommendations that should be considered in its use, which has become mopre popular and widely used as a safe filling.


REFERENCES

  1. Rohrich RJ, Rios JL, Fagien S. Role of new fillersin facial rejuvenation: A cautious outlook. Plast Reconstr Surg 2003; 112(7): 1899-902.

  2. Olenius M. The first clinical study using a new biodegradable implant for the treatment of lips, wrinkles, and folds. Aesthetic Plast Surg 1988; 22(2): 97-101.

  3. Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: Treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29(8): 802-9.

  4. Q-Med AB. Restylane (Investigators Brochure). Uppsala, Sweden: Q-Med AB, 1996.

  5. Broder KW, Cohen SR. An overview of Semipermanent and Permanent Fillers. Plast Reconstr Surg 2006; 118(3S) (Suppl):7S-14S.

  6. U.S. Food and Drug Administration. Restylane. Available at www.fda.gov/cdrh/pdf4/p040024.html. Washington, D.C.: Food and Drug Administration. Accessed August 9, 2007.

  7. Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 2002; 28(6): 491-4.

  8. Laurent TC. Biochemistry of hyaluronan. Acta Otolaryngol 1987; 442: 7-24.

  9. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation: A clinical and histological study. Dermatol Surg 1998; 24(12): 1317-25.

  10. Glogau RG. Aesthetic and anatomic analysis of the aging skin. Semin Cutan Med Surg 1996; 15(3): 134-8.

  11. Fitzpatrick RE, Goldman MP, Satur NM, Tope WD. Pulsed carbon dioxide laser resurfacing of photo-aged facial skin. Arch Dermatol 1996; 132(4): 395-402.

  12. Lemperle G, Holmes RE, Cohen SR, Lemperle SM. A classification of facial wrinkles. Plast Reconstr Surg 2001; 108(6): 1735-50.

  13. Shafir R, Amir A, Gur E. Long-term complications of facial injection with Restylane (injectable hyaluronic acid). Plast Reconstr Surg 2000; 106(5): 1215.

  14. Lupton JR, Alster TS. Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel. Dermatol Surg 2000; 26(2): 135-7.

  15. Vartanian AJ, Frankel AS, Rubin MG. Injected hyaluronidase reduces Restylane-mediated cutaneous augmentation. Arch Facial Plast Surg 2005; 7(4): 231-7.

  16. Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg 2005; 31(8Pt 1): 893-7.

  17. Lambros V. The use of hyaluronidase to reverse the effects of hyaluronic acid filler. Plast Reconstr Surg 2004; 114(1): 277.




2020     |     www.medigraphic.com